Agenus (NASDAQ:AGEN) Upgraded at StockNews.com

Agenus (NASDAQ:AGEN) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other brokerages also recently issued reports on AGEN. Robert W. Baird decreased their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, March 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.75.

Agenus Trading Down 3.6 %

NASDAQ:AGEN opened at $1.61 on Friday. The firm has a market cap of $40.75 million, a PE ratio of -0.14 and a beta of 1.23. The stock has a fifty day moving average price of $3.01 and a 200 day moving average price of $3.67. Agenus has a 12-month low of $1.60 and a 12-month high of $19.69.

Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. Equities analysts forecast that Agenus will post -12.55 EPS for the current year.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently made changes to their positions in AGEN. Corton Capital Inc. acquired a new stake in shares of Agenus during the fourth quarter worth about $36,000. Virtu Financial LLC acquired a new stake in shares of Agenus during the fourth quarter worth about $51,000. Apollon Wealth Management LLC acquired a new stake in shares of Agenus during the fourth quarter worth about $55,000. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the third quarter worth about $55,000. Finally, Bank of Montreal Can acquired a new stake in shares of Agenus during the fourth quarter worth about $69,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.